nach oben

Erschienen in:

24.01.2014 | zertifizierte fortbildung

Placeboeffekte und ihre Implikationen in der Neurologie

Positive Erwartung, Konditionierung, Lernprozess

verfasst von: Prof. Dr. med. Ulrike Bingel

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aktuelle neurowissenschaftliche und klinische Befunde zu positiven physiologischen oder psychologischen Veränderungen nach Einnahme von Medikamenten ohne spezifische Wirkstoffe oder Scheineingriffen haben wichtige Implikationen für die praktische Behandlung. Diese „Placeboeffekte“ sind besonders für Patienten mit neurologischen Erkrankungen relevant.

Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nature reviews Drug discovery. 2013;12(3):191–204. Epub 2013/03/02.PubMedCrossRef

Klinger R. [The potential of the analgetic placebo effect - s3-guideline recommendation on the clinical use for acute and perioperative pain management]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2010;45(1):22–9. Epub 2010/01/22. Das Potenzial des analgetischen Placeboeffektes - S3-Leitlinien-Empfehlung zur Behandlung akuter und perioperativer Schmerzen. rklinger@uni-hamburg.de.PubMedCrossRef

Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999;19(1):484–94.PubMed

Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci. 2003;23(10):4315–23.PubMed

Goebel MU, Trebst AE, Steiner J, Xie YF, Exton MS, Frede S, et al. Behavioral conditioning of immunosuppression is possible in humans. Faseb J. 2002;16(14):1869–73.PubMedCrossRef

Vase L, Riley JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain. 2002;99(3):443–52.PubMedCrossRef

Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344(21):1594–602.PubMedCrossRef

Vase L, Petersen GL, Riley JL, 3rd, Price DD. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain. 2009;145(1–2):36–44.PubMedCrossRef

Krogsboll LT, Hrobjartsson A, Gotzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC medical research methodology. 2009;9:1. Epub 2009/01/07.PubMedCentralPubMedCrossRef

10.

Rutherford BR, Mori S, Sneed JR, Pimontel MA, Roose SP. Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. Journal of psychiatric research. 2012;46(6):697–702. Epub 2012/03/14.PubMedCentralPubMedCrossRef

11.

Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2(8091):654–7.PubMedCrossRef

12.

Eippert F, Finsterbusch J, Bingel U, Buchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science. 2009;326(5951):404.PubMedCrossRef

13.

Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63(4):533–43.PubMedCrossRef

14.

Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005;25(34):7754–62. Epub 2005/08/27.PubMedCrossRef

15.

Wager TD, Scott DJ, Zubieta JK. Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci U S A. 2007;104(26):11056–61.PubMedCentralPubMedCrossRef

16.

Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature medicine. 2011;17(10):1228–30. Epub 2011/10/04.PubMedCrossRef

17.

Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M. Placebo in emotional processing—induced expectations of anxiety relief activate a generalized modulatory network. Neuron. 2005;46(6):957–69. Epub 2005/06/15.PubMedCrossRef

18.

Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159(5):728–37.PubMedCrossRef

19.

Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci. 2008;28(49):13066–74.PubMedCrossRef

20.

Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol. 2009;29(4):372–7.PubMedCrossRef

21.

de La Fuente-Fernandez R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, et al. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab. 2001;21(10):1151–9.CrossRef

22.

Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004;7(6):587–8.PubMedCrossRef

23.

Benedetti F, Lanotte M, Colloca L, Ducati A, Zibetti M, Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol. 2009;587(Pt 15):3869–83.PubMedCrossRef

24.

Schweinhardt P, Seminowicz DA, Jaeger E, Duncan GH, Bushnell MC. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. J Neurosci. 2009;29(15):4882–7. Epub 2009/04/17.PubMedCrossRef

25.

Benedetti F, Carlino E, Pollo A. Hidden administration of drugs. Clin Pharmacol Ther. 2011;90(5):651–61.PubMedCrossRef

26.

Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F. Response expectancies in placebo analgesia and their clinical relevance. Pain. 2001;93(1):77–84.PubMedCrossRef

27.

Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol. 2004;3(11):679–84.PubMedCrossRef

28.

Kirk JM, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1998;59(2):287–93.PubMedCrossRef

29.

Metrik J, Rohsenow DJ, Monti PM, McGeary J, Cook TA, de Wit H, et al. Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol. 2009;17(4):217–25.PubMedCentralPubMedCrossRef

30.

Volkow ND, Wang GJ, Ma Y, Fowler JS, Zhu W, Maynard L, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci. 2003;23(36):11461–8.PubMed

31.

Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3(70):70ra14.PubMedCrossRef

32.

Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. Journal of affective disorders. 2009;118(1–3):1–8. Epub 2009/02/28.PubMedCrossRef

33.

Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Archives of internal medicine. 2006;166(2):155–60. Epub 2006/01/25.PubMedCrossRef

34.

Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis care & research. 2010;62(6):791–9. Epub 2010/03/02.CrossRef

35.

Klinger R. The potential of the analgetic placebo effect - s3-guideline recommendation on the clinical use for acute and perioperative pain management. Anasthesiol Intensivmed Notfallmed Schmerzther.45(1):22–9.

36.

Miller FG, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioeth. 2009;9(12):39–47.PubMedCrossRef

37.

Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Bmj. 2008;336(7651):999–1003.PubMedCrossRef

38.

Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci. 2012;33(3):165–72. Epub 2012/01/31.PubMedCrossRef

39.

Goebel MU, Meykadeh N, Kou W, Schedlowski M, Hengge UR. Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom. 2008;77(4):227–34.PubMedCrossRef

40.

Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? Journal of developmental and behavioral pediatrics: JDBP. 2010;31(5):369–75. Epub 2010/05/25.PubMedCentralPubMedCrossRef

41.

Ader R, Cohen N. Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus. Science. 1982;215(4539):1534–6. Epub 1982/03/19.PubMedCrossRef

42.

Schedlowski M, Pacheco-Lopez G. The learned immune response: Pavlov and beyond. Brain, behavior, and immunity. 2010;24(2):176–85. Epub 2009/08/25.PubMedCrossRef

43.

Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PloS one. 2012;7(10):e48135. Epub 2012/10/31.PubMedCentralPubMedCrossRef

44.

Stein N, Sprenger C, Scholz J, Wiech K, Bingel U. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain. 2012;153(11):2210–7. Epub 2012/09/11.PubMedCrossRef

45.

Kong J, Jensen K, Loiotile R, Cheetham A, Wey H-Y, Tan Y, et al. Functional connectivity of frontoparietal network predicts cognitive modulation of pain. Pain. 2012;in press.

46.

Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain. 2012;153(12):2393–402. Epub 2012/09/19.PubMedCentralPubMedCrossRef

47.

Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I, et al. Loss of expectation-related mechanisms in Alzheimer’s disease makes analgesic therapies less effective. Pain. 2006;121(1–2):133–44.PubMedCrossRef

48.

Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials. Clin Pharmacol Ther. 2011.

49.

Laferton JA, Shedden Mora M, Auer CJ, Moosdorf R, Rief W. Enhancing the efficacy of heart surgery by optimizing patients’ preoperative expectations: study protocol of a randomized controlled trial. American heart journal. 2013;165(1):1–7. Epub 2012/12/15.PubMedCrossRef

Titel: Placeboeffekte und ihre Implikationen in der Neurologie
Positive Erwartung, Konditionierung, Lernprozess
verfasst von: Prof. Dr. med. Ulrike Bingel
Publikationsdatum: 24.01.2014
Verlag: Urban & Vogel
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 1/2014
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-013-0310-4

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Placeboeffekte und ihre Implikationen in der Neurologie

Positive Erwartung, Konditionierung, Lernprozess

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Plättchenhemmer allein oder im „Duett“?

Computerspiel- und Internetsucht — Manual für die Praxis

Antidot für den Notfall

Prolongiertes Opiod bietet eine wirksame und sichere Off-label-Therapie

Selten, aber behandelbar

Pflaster-Generikum

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein